more on VKTX Viking Therapeutics priced concurrent offerings of 7,857,143 shares at $35 each and $225M in convertible notes, with settlement scheduled for September 25, 2026. •    Larger offerings: Viking increased both the stock offering and the note offering from their previously announced $200M sizes. •    Note terms: The senior unsecured notes pay 2.00% annual interest and mature October 15, 2032. •    Conversion price: The initial price is approximately $50.75 per share, about 45% above the stock offering price. •    Estimated proceeds: Viking expects approximately $258.2M net from stock and $218.0M net from notes, excluding underwriter options. •    Funding plans: Proceeds will support the VK2735 and VK3019 programs, other research and development, working capital, and general corporate purposes. 24-SEP-2026 07:50 AM ET